Indication Regorafenib is indicated for patients with mCRC who have previously received and progressed on or after the following treatments: Fluoropyrimidine-based chemotherapy Oxaliplatin Irinotecan An anti-VEGF (vascular endothelial growth factor) therapy (e.g., bevacizumab) If their cancer is RAS wild-type, an anti-EGFR (epidermal growth factor receptor) therapy (e.g., cetuximab or panitumumab)
Indication First-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
Indication First-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (mCRC).
Indication For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.
1 Westmount Square, Suite 1630
Westmount, QC H3Z 2P9
Canada
info@colorectalcancercanada.com
© Colorectal Cancer Canada All rights reserved
Charitable registration number 86657 2423 RR0001
